Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Fry

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Biopolymers|September 30, 2006
Protein-protein interactions as targets for small molecule drug discoveryDavid C Fry
Current Pharmaceutical Design|June 2, 2012
Small-molecule inhibitors of protein-protein interactions: how to mimic a protein partnerDavid C Fry
Methods in Molecular Biology (Clifton, N.J.)|April 11, 2015
Targeting protein-protein interactions for drug discoveryDavid C Fry
Journal of Molecular Medicine (Berlin, Germany)|November 12, 2005
Targeting protein-protein interactions for cancer therapyDavid C Fry, Lyubomir T Vassilev
Methods in Enzymology|December 13, 2005
Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspectsDavid C Fry, Bradford Graves, Lyubomir T Vassilev
Future Medicinal Chemistry|November 22, 2011
Druggability assessment of protein-protein interfacesJutta Wanner, David C Fry, Zhengwei Peng, et al.
Journal of Biomolecular NMR|September 1, 2005
1H, 15N, and 13C resonance assignments of human interleukin-2David C Fry, S Donald Emerson, Chao-Min Liu, et al.
Journal of Biomolecular NMR|November 24, 2004
NMR structure of a complex between MDM2 and a small molecule inhibitorDavid C Fry, S Donald Emerson, Stefan Palme, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitorDavid C Fry, Charles Wartchow, Bradford Graves, et al.
Bioorganic & Medicinal Chemistry|April 28, 2004
A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptidesHongmao Sun, David N Greeley, Xin-Jie Chu, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Biopolymers|September 30, 2006
Protein-protein interactions as targets for small molecule drug discoveryDavid C Fry
Current Pharmaceutical Design|June 2, 2012
Small-molecule inhibitors of protein-protein interactions: how to mimic a protein partnerDavid C Fry
Methods in Molecular Biology (Clifton, N.J.)|April 11, 2015
Targeting protein-protein interactions for drug discoveryDavid C Fry
Journal of Molecular Medicine (Berlin, Germany)|November 12, 2005
Targeting protein-protein interactions for cancer therapyDavid C Fry, Lyubomir T Vassilev
Methods in Enzymology|December 13, 2005
Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspectsDavid C Fry, Bradford Graves, Lyubomir T Vassilev
Future Medicinal Chemistry|November 22, 2011
Druggability assessment of protein-protein interfacesJutta Wanner, David C Fry, Zhengwei Peng, et al.
Journal of Biomolecular NMR|September 1, 2005
1H, 15N, and 13C resonance assignments of human interleukin-2David C Fry, S Donald Emerson, Chao-Min Liu, et al.
Journal of Biomolecular NMR|November 24, 2004
NMR structure of a complex between MDM2 and a small molecule inhibitorDavid C Fry, S Donald Emerson, Stefan Palme, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitorDavid C Fry, Charles Wartchow, Bradford Graves, et al.
Bioorganic & Medicinal Chemistry|April 28, 2004
A predictive pharmacophore model of human melanocortin-4 receptor as derived from the solution structures of cyclic peptidesHongmao Sun, David N Greeley, Xin-Jie Chu, et al.
Pageof 2